165 related articles for article (PubMed ID: 30354399)
21. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.
Mattumpuram J; Maniya MT; Fernandes CAL; Sohail CS; Ahmed A; Khan R; Hamza M; Ali K
Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102167. PubMed ID: 37871711
[TBL] [Abstract][Full Text] [Related]
22. Short-term effects of angiotensin receptor-neprilysin inhibitors on diastolic strain and tissue doppler parameters in heart failure patients with reduced ejection fraction: A pilot trial.
Nakou ES; Marketou ME; Patrianakos A; Protonotarios A; Vardas PE; Parthenakis FI
Hellenic J Cardiol; 2020; 61(6):415-418. PubMed ID: 31866286
[TBL] [Abstract][Full Text] [Related]
23. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
[TBL] [Abstract][Full Text] [Related]
24. Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
Thonsgaard S; Prickett TCR; Hansen LH; Wewer Albrechtsen NJ; Andersen UØ; Terzic D; Plomgaard P; Gustafsson F; Goetze JP; Mark PD
Clin Chem; 2022 May; 68(5):713-720. PubMed ID: 35175317
[TBL] [Abstract][Full Text] [Related]
25. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
Florea VG; Rector TS; Anand IS; Cohn JN
Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037
[TBL] [Abstract][Full Text] [Related]
26. Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.
Murphy SP; Ward JH; Piña IL; Felker GM; Butler J; Maisel AS; Meng X; Prescott MF; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Dec; 10(12):976-988. PubMed ID: 36456072
[TBL] [Abstract][Full Text] [Related]
27. Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: Implication for diagnosis of diastolic heart failure.
Lim TK; Ashrafian H; Dwivedi G; Collinson PO; Senior R
Eur J Heart Fail; 2006 Jan; 8(1):38-45. PubMed ID: 16115798
[TBL] [Abstract][Full Text] [Related]
28. The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction.
Kim H; Jun DW; Cho YK; Nam CW; Han SW; Hur SH; Kim YN; Kim KB
Echocardiography; 2008 Oct; 25(9):961-7. PubMed ID: 18771554
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
Vasquez N; Carter S; Grodin JL
Curr Heart Fail Rep; 2020 Jun; 17(3):67-76. PubMed ID: 32394149
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence.
Bracun V; van Essen B; Voors AA; van Veldhuisen DJ; Dickstein K; Zannad F; Metra M; Anker S; Samani NJ; Ponikowski P; Filippatos G; Cleland JGF; Lang CC; Ng LL; Shi C; de Wit S; Aboumsallem JP; Meijers WC; Klip IT; van der Meer P; de Boer RA
ESC Heart Fail; 2022 Dec; 9(6):4167-4176. PubMed ID: 36088651
[TBL] [Abstract][Full Text] [Related]
32. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea.
Ibrahim NE; Afilalo M; Chen-Tournoux A; Christenson RH; Gaggin HK; Hollander JE; Kastner P; Levy PD; Mang A; Masson S; Nagurney JT; Nowak RM; Pang PS; Peacock WF; Dipl-Stat VR; Walters EL; Januzzi JL
JACC Heart Fail; 2020 May; 8(5):415-422. PubMed ID: 32354416
[TBL] [Abstract][Full Text] [Related]
34. Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
Dalos D; Mascherbauer J; Zotter-Tufaro C; Duca F; Kammerlander AA; Aschauer S; Bonderman D
J Am Coll Cardiol; 2016 Jul; 68(2):189-99. PubMed ID: 27386773
[TBL] [Abstract][Full Text] [Related]
35. Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.
Barroso MC; Kramer F; Greene SJ; Scheyer D; Köhler T; Karoff M; Seyfarth M; Gheorghiade M; Dinh W
BMC Cardiovasc Disord; 2016 Oct; 16(1):199. PubMed ID: 27769173
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
37. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
Kobayashi M; Ferreira JP; Duarte K; Bresso E; Huttin O; Bozec E; Brunner La Rocca HP; Delles C; Clark AL; Edelmann F; González A; Heymans S; Pellicori P; Petutschnigg J; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F; Girerd N;
Eur J Heart Fail; 2024 May; 26(5):1231-1241. PubMed ID: 38528728
[TBL] [Abstract][Full Text] [Related]
38. Triphasic mitral inflow velocity with mid-diastolic flow: the presence of mid-diastolic mitral annular velocity indicates advanced diastolic dysfunction.
Ha JW; Ahn JA; Moon JY; Suh HS; Kang SM; Rim SJ; Jang Y; Chung N; Shim WH; Cho SY
Eur J Echocardiogr; 2006 Jan; 7(1):16-21. PubMed ID: 16378917
[TBL] [Abstract][Full Text] [Related]
39. Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure.
Zhu M; Guo J; Qiqike B; Nay X; Dan S; Kuransi A; Hu G; Han Z; Hou D; Aili A; Xia B; Chen P; Bate B; Xie J
Int Heart J; 2023; 64(6):1032-1039. PubMed ID: 38030290
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
